<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159921" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Moxifloxacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Humma</surname>
            <given-names>Zil E</given-names>
          </name>
          <aff>University of Veterinary and Animal Sciences, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zil E Humma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159921.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Moxifloxacin is a potent fluoroquinolone antibiotic that is effective against a wide range of bacterial infections. Bayer AG developed the drug&#x000a0;in the late 1990s, and it&#x000a0;received approval from the U.S. Food and Drug Administration (FDA) in 1999 for&#x000a0;the treatment of&#x000a0;respiratory infections,&#x000a0;making it a valuable addition to the antibiotic arsenal due to its broad-spectrum coverage.<xref ref-type="bibr" rid="article-159921.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Moxifloxacin is highly effective in addressing various bacterial infections. Moxifloxacin is FDA-approved for the treatment of community-acquired pneumonia (CAP) caused by susceptible strains of&#x000a0;<italic toggle="yes">Streptococcus pneumonia&#x000a0;</italic>and&#x000a0;<italic toggle="yes">Mycoplasma pneumonia,</italic>&#x000a0;acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, complicated skin and skin structure infections, including cellulitis, abscesses, and surgical wound infections, uncomplicated skin and skin structure infections, complicated intra-abdominal infections, and the treatment of plague, including pneumonic and septicemic forms, caused by&#x000a0;<italic toggle="yes">Yersinia pestis</italic>.<xref ref-type="bibr" rid="article-159921.r2">[2]</xref><xref ref-type="bibr" rid="article-159921.r3">[3]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Moxifloxacin is occasionally used off-label for treating other conditions, such as uncomplicated urinary tract infections. However, the utilization of the drug is typically reserved for situations where alternative antibiotics prove ineffective or inappropriate due to resistance patterns. Although its effectiveness can vary, moxifloxacin can also be used to treat&#x000a0;chronic bacterial prostatitis after the failure of other antibiotics.&#x000a0;Moxifloxacin has been contemplated as a component of multidrug therapy for drug-resistant tuberculosis. The endorsement of moxifloxacin usage for multidrug-resistant tuberculosis is supported by guidelines from the American Thoracic Society (ATS), the Infectious Diseases Society of America (IDSA), the Centers for Disease Control and Prevention (CDC), and the European Respiratory Society (ERS).<xref ref-type="bibr" rid="article-159921.r4">[4]</xref>&#x000a0;In certain situations, moxifloxacin may be used to exacerbate chronic obstructive pulmonary disease (COPD), especially when there are concerns about&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>&#x000a0;infection.<xref ref-type="bibr" rid="article-159921.r5">[5]</xref></p>
      </sec>
      <sec id="article-159921.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Moxifloxacin exerts its pharmacological effect by inhibiting bacterial DNA synthesis and replication. Moxifloxacin specifically targets 2 crucial enzymes involved in the bacterial DNA replication process&#x02014;DNA gyrase and topoisomerase IV. By binding to these enzymes, moxifloxacin prevents their ability to unwind and repair DNA strands, resulting in DNA damage and the inhibition of bacterial growth. This mechanism disrupts the bacteria's capacity to reproduce and survive, rendering moxifloxacin effective against a wide range of bacterial infections.<xref ref-type="bibr" rid="article-159921.r6">[6]</xref>&#x000a0;</p>
        <p>Respiratory fluoroquinolones, such as moxifloxacin and levofloxacin,&#x000a0;exhibit effectiveness against pivotal causative pathogens, including<italic toggle="yes">&#x000a0;S pneumonia, M pneumoniae, Chlamydia pneumoniae, Legionella pneumophila,</italic>&#x000a0;and various other organisms. Due to their broad-spectrum activity and proven efficacy, these drugs are frequently utilized as standalone therapies for CAP. These drugs are classified as respiratory fluoroquinolones due to their unique chemical structure and potent affinity for targeting pathogens commonly found in respiratory tract infections.<xref ref-type="bibr" rid="article-159921.r7">[7]</xref><xref ref-type="bibr" rid="article-159921.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Moxifloxacin can be administered with or without food, and following&#x000a0;oral administration, moxifloxacin is absorbed well in the body, displaying an estimated bioavailability of around 90%.</p>
        <p><bold>Distribution:</bold>&#x000a0;With a substantial volume of distribution, moxifloxacin effectively permeates diverse tissues, encompassing the lungs, skin, and prostate. In addition, the drug exhibits favorable penetration into the cerebrospinal fluid.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Moxifloxacin undergoes minimal hepatic metabolism, primarily through glucuronidation, and produces inactive metabolites. Notably, the metabolism of moxifloxacin is minimally influenced by cytochrome P450 enzymes.</p>
        <p><bold>Elimination:</bold>&#x000a0;The predominant route of elimination for moxifloxacin and its metabolites is through unchanged excretion in the urine. Approximately 45% to 48% of the administered dose is excreted in the urine, primarily in its unchanged form, whereas the remaining portion is eliminated through feces.</p>
        <p>The half-life of moxifloxacin is approximately 12 hours, supporting once-daily dosing in most clinical scenarios. The pharmacokinetics of moxifloxacin exhibit consistency across diverse populations, with no significant differences between genders or age groups. However, dosage adjustments may be necessary in patients with impaired renal function to account for reduced drug clearance.<xref ref-type="bibr" rid="article-159921.r9">[9]</xref><xref ref-type="bibr" rid="article-159921.r10">[10]</xref></p>
      </sec>
      <sec id="article-159921.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and&#x000a0;Strengths</bold>
</p>
        <p>Moxifloxacin is typically administered orally&#x000a0;and is available in tablet or oral suspension formulations, facilitating systemic absorption through the digestive tract. In healthcare settings, intravenous (IV) administration is also an option, particularly for more severe infections or situations where oral administration is not feasible. Moxifloxacin is generally not administered rectally, topically, epidurally, intracerebrally, or through enteral routes. The primary modes of delivery for the drug are oral and IV, facilitating systemic distribution and targeting a broad spectrum of infections throughout the body. Localized topical preparations of moxifloxacin may be available for specific eye or ear infections, but these formulations are not administered via routes such as rectal, epidural, or intracerebral means.<xref ref-type="bibr" rid="article-159921.r11">[11]</xref><xref ref-type="bibr" rid="article-159921.r12">[12]</xref></p>
        <p>Moxifloxacin tablets are offered in strengths of 400 mg and 600 mg. The oral suspension, with a strength of 400 mg/5 mL, is commonly used in pediatric cases or situations where swallowing tablets poses a challenge. Moxifloxacin IV solutions are available in strengths&#x000a0;of 400 mg/250 mL, and they are utilized in hospitals and healthcare settings, particularly for more severe infections or instances where oral medications cannot be administered.<xref ref-type="bibr" rid="article-159921.r13">[13]</xref><xref ref-type="bibr" rid="article-159921.r14">[14]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The recommended adult dosage of moxifloxacin for respiratory tract infections such as pneumonia and bronchitis, skin and soft tissue infections, intra-abdominal infections, acute bacterial sinusitis, and COPD exacerbations is typically 400 mg. Notably, the standard dosage of moxifloxacin is generally 400 mg once daily. The duration of pharmacotherapy varies based on the type and severity of the infection.<xref ref-type="bibr" rid="article-159921.r15">[15]</xref><xref ref-type="bibr" rid="article-159921.r16">[16]</xref>&#x000a0;According to FDA-approved product labeling for CAP, a regimen of 7 to 14 days is advised. For uncomplicated skin and skin structure infections, a 7-day course of moxifloxacin is advised. Treatment should extend from 7 to 21 days for cases of complicated skin and skin structure infection.</p>
        <p>Complicated intra-abdominal infections necessitate a 5- to 14-day course, while plague requires a 10- to 14-day treatment. For acute bacterial exacerbation of chronic bronchitis, a 5-day course is recommended. Acute bacterial sinusitis necessitates 10 days of treatment.&#x000a0;In clinical studies involving individuals with CAP, acute sinusitis, or acute exacerbations of chronic bronchitis (AECB), moxifloxacin administered at a daily dose of 400 mg demonstrated success rates, either in terms of bacteriological or clinical improvement, reaching approximately 90% or greater success.<xref ref-type="bibr" rid="article-159921.r1">[1]</xref>&#x000a0;</p>
        <p>Moxifloxacin exhibited equivalent efficacy to amoxicillin 1 g thrice daily and clarithromycin 500 mg twice daily for the treatment of CAP. Moreover, in AECB, moxifloxacin demonstrated comparable effectiveness to clarithromycin. In patients with sinusitis, a 7-day regimen of moxifloxacin at 400 mg once daily proved equally effective compared to a 10-day course of cefuroxime at 250 mg twice daily.<xref ref-type="bibr" rid="article-159921.r2">[2]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Patients with mild-to-moderate hepatic impairment generally do not necessitate a significant dosage adjustment of moxifloxacin. However, in cases of severe hepatic impairment, a dosage reduction is recommended. Routine monitoring of liver function tests, including serum transaminases&#x02014;alanine transaminase (ALT) and aspartate transaminase (AST)&#x02014;levels, is advised to detect any signs of adverse effects or changes in liver function during moxifloxacin treatment. Although hepatotoxicity associated with moxifloxacin is rare, individuals with preexisting liver conditions may be at a higher risk.<xref ref-type="bibr" rid="article-159921.r17">[17]</xref><xref ref-type="bibr" rid="article-159921.r18">[18]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;Dosage adjustments of moxifloxacin are essential in patients with renal impairment. The extent of adjustment will be determined by the degree of renal dysfunction, typically assessed through creatinine clearance (CrCl). Patients with renal impairment should undergo regular monitoring of their renal function, including assessments of serum creatinine levels and the calculation of CrCl. In individuals undergoing hemodialysis, it is advisable to administer moxifloxacin after dialysis sessions to ensure adequate drug levels.<xref ref-type="bibr" rid="article-159921.r19">[19]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Moxifloxacin use during pregnancy should be evaluated on a case-by-case basis, carefully balancing potential benefits against potential risks to the developing fetus. Animal studies have indicated the potential for moxifloxacin to cause congenital disabilities, particularly during the organogenesis period, which is the first trimester.&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;As moxifloxacin is known to be excreted in breast milk, it poses&#x000a0;a potential risk of the infant being exposed to the medication through breastfeeding. Healthcare providers should contemplate alternative antibiotics with a more established safety profile during breastfeeding, particularly for non-life-threatening infections. The potential risk of the infant being exposed to the medication through breastfeeding should be taken into consideration.</p>
        <p>Healthcare providers should explore alternative antibiotics with a well-established safety profile during breastfeeding, particularly for non-life-threatening infections. The administration of an eye drop containing moxifloxacin by a lactating mother carries minimal risk to the nursing infant. To significantly reduce the transfer of the drug into breast milk after the application of eye drops, gentle pressure should be applied to the tear duct near the eye's corner for 1 minute or more. Any excess solution should be removed using an absorbent tissue.<xref ref-type="bibr" rid="article-159921.r20">[20]</xref><xref ref-type="bibr" rid="article-159921.r21">[21]</xref></p>
        <p><bold>Pediatric patients: </bold>The systemic use of moxifloxacin is not approved by the FDA for pediatric use. Moreover, preclinical studies have indicated that moxifloxacin can induce arthropathy in juvenile animals. However, the efficacy and safety of moxifloxacin ophthalmic solution have been established across all age groups. Clinical studies in adults, children, and neonates provide robust evidence supporting the use of moxifloxacin. Notably,&#x000a0;the ophthalmic administration of moxifloxacin ophthalmic solution does not have any impact on weight-bearing joints, unlike certain orally administered quinolones. This is significant because&#x000a0;the oral intake of some quinolones has been associated with arthropathy in immature animals.</p>
        <p><bold>Older patients:</bold> Older&#x000a0;patients, particularly those on corticosteroids, are at an increased risk of severe tendon disorders, including rupture, when treated with fluoroquinolones such as moxifloxacin. In addition, there is an elevated incidence of aortic aneurysm and dissection within 2 months after fluoroquinolone use in older patients. As moxifloxacin injection contains sodium, caution should be exercised in patients with congestive heart failure. Although clinical trials indicate no significant difference in safety and efficacy for oral moxifloxacin in patients 65 or older, caution is still warranted. Older patients may be more susceptible to drug-induced QT interval prolongation, so prudent use is advised, and concurrent administration with QT-prolonging drugs should be avoided.</p>
      </sec>
      <sec id="article-159921.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Moxifloxacin is associated with various adverse effects and can result in severe injuries in some cases. The common adverse drug reactions include gastrointestinal symptoms such as nausea, abdominal pain, vomiting, and diarrhea. Patients may experience headaches, dizziness, and, in rare cases, more severe central nervous system (CNS) effects such as confusion or hallucinations. A significant and potentially severe adverse effect of moxifloxacin is the increased risk of tendonitis and tendon rupture, especially in older adults and those concurrently using corticosteroids. Reports indicate that moxifloxacin can lead to changes in heart rhythm (QTc interval prolongation) and an elevated risk of arrhythmias, especially in patients with preexisting heart conditions. Some patients may experience skin rashes, itching, lips, face, and throat swelling due to an allergic reaction to moxifloxacin. Severe allergic reactions such as anaphylaxis are rare but possible.&#x000a0;Moxifloxacin has been associated with increased photosensitivity, potentially resulting in heightened susceptibility to sunburn. According to the reports, there are indications of musculoskeletal pain and joint discomfort.<xref ref-type="bibr" rid="article-159921.r22">[22]</xref><xref ref-type="bibr" rid="article-159921.r23">[23]</xref></p>
        <p>Notably, although most individuals tolerate moxifloxacin well with few or no adverse effects, these potential adverse effects should be considered, particularly when evaluating the risk-benefit profile for prescribing this medication. Patients should be educated about these possible reactions, and if they experience any concerning symptoms, they should seek medical attention promptly. Moxifloxacin should be used carefully and reserved for situations where other antibiotics are unsuitable, considering its potential for adverse effects. Patients with preexisting comorbidities or those taking medications such as QT-prolonging drugs may face an elevated risk of experiencing these adverse effects.&#x000a0;Thus, close monitoring is essential when these individuals are prescribed moxifloxacin.<xref ref-type="bibr" rid="article-159921.r24">[24]</xref><xref ref-type="bibr" rid="article-159921.r25">[25]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Concurrent use of moxifloxacin with antacids, sucralfate, or multivitamins containing aluminum, magnesium, iron, or zinc can reduce the absorption of the drug. Therefore, it is advisable to administer moxifloxacin at least 4 hours before or 8 hours after taking these products. Combining moxifloxacin with other quinolone antibiotics should be avoided due to an increased risk of adverse effects.<xref ref-type="bibr" rid="article-159921.r26">[26]</xref>&#x000a0;Certain&#x000a0;nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, may increase the risk of adverse effects on the CNS when taken with moxifloxacin. Therefore, caution is advised when combining these medications. Simultaneously using corticosteroids, such as prednisone, with moxifloxacin may increase the risk of tendonitis and tendon rupture, so concurrent use should be avoided if possible.</p>
        <p>Moxifloxacin may increase the anticoagulant effect of drugs such as warfarin, potentially leading to an increased risk of bleeding. Close monitoring of blood clotting parameters may be necessary when these drugs are used together. Combining moxifloxacin with certain antiarrhythmic drugs, such as quinidine, procainamide, amiodarone, and sotalol, can increase the risk of QT interval prolongation and potentially lead to life-threatening cardiac arrhythmias.<xref ref-type="bibr" rid="article-159921.r27">[27]</xref>&#x000a0;This combination should be avoided or used cautiously under close medical supervision.</p>
        <p>Moxifloxacin can increase serum levels of theophylline, necessitating adjustments in theophylline dosage when taken concomitantly. Reports suggest an increased risk of CNS stimulation and seizures when moxifloxacin is used concurrently with selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine. Therefore, caution is advised, and close monitoring is recommended if both are used together. As combining moxifloxacin with duloxetine&#x02014;a medication used to treat depression and anxiety&#x02014;may increase the risk of serotonin syndrome, careful monitoring is needed if these drugs are taken together. Furthermore, when taken with insulin or oral hypoglycemic agents, moxifloxacin may affect blood glucose levels, potentially leading to hypo- or hyperglycemia. Thus, regular blood glucose monitoring and dosage adjustments may be necessary.<xref ref-type="bibr" rid="article-159921.r28">[28]</xref></p>
      </sec>
      <sec id="article-159921.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Moxifloxacin is contraindicated in individuals with known hypersensitivity or allergic reactions to moxifloxacin or other fluoroquinolone antibiotics.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>The FDA warns of tendon disorders associated with fluoroquinolone use, including tendonitis or rupture. Moxifloxacin is contraindicated for patients with a history of myasthenia gravis due to the risk of exacerbating muscle weakness.<xref ref-type="bibr" rid="article-159921.r29">[29]</xref> Concerns arise about its safety in individuals younger than 18, as it may potentially impact developing musculoskeletal structures.<xref ref-type="bibr" rid="article-159921.r30">[30]</xref>&#x000a0;Fluoroquinolones, including moxifloxacin, increase the risk of sensory or sensorimotor axonal polyneuropathy, leading to paresthesias, hypoesthesias, dysesthesias, and muscle weakness. Neuropathy may manifest soon after administration and can be irreversible. Therefore, prompt cessation of moxifloxacin is required upon the presentation of peripheral neuropathy symptoms, including pain, burning, tingling, numbness, or weakness. Caution should be exercised when administering fluoroquinolones, including moxifloxacin, to patients with a history of peripheral neuropathy.<xref ref-type="bibr" rid="article-159921.r31">[31]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Moxifloxacin is generally avoided during pregnancy and breastfeeding unless the potential benefits outweigh the risks, as it may adversely affect fetal development and pass into breast milk. Caution is warranted when prescribing moxifloxacin to individuals with a history of epilepsy or other seizure disorders due to its potential to reduce the threshold and increase the risk of seizures.<xref ref-type="bibr" rid="article-159921.r32">[32]</xref>&#x000a0;</p>
        <p>Moxifloxacin can cause QT interval prolongation on an electrocardiogram (ECG), necessitating cautious use in individuals with a history of arrhythmias or those taking medications that also prolong the QT interval. Individuals with severe liver impairment should avoid moxifloxacin or use it cautiously, as it may exacerbate liver dysfunction. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency&#x02014;a genetic enzyme deficiency&#x02014;should exercise caution when using moxifloxacin, as it can trigger hemolysis (breakdown of red blood cells) in individuals with this condition.<xref ref-type="bibr" rid="article-159921.r33">[33]</xref>&#x000a0;</p>
        <p>The risk of aortic aneurysm and dissection is higher in the 2 months following fluoroquinolone use, especially among older individuals. The underlying cause for this heightened risk remains uncertain. In cases where patients have a confirmed aortic aneurysm or are at an elevated risk for such conditions, it is recommended to consider moxifloxacin as a treatment option only when no alternative antibacterial treatments are feasible.<xref ref-type="bibr" rid="article-159921.r34">[34]</xref></p>
      </sec>
      <sec id="article-159921.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The therapeutic index (TI) serves as an indicator of a drug's safety profile, and is calculated by comparing the dose required to induce toxicity in 50% of a population (TD50) with the dosage that yields therapeutic effects in 50% of the population (ED50). This ratio provides valuable insights into the drug's margin of safety. The high therapeutic index of moxifloxacin implies that the effective therapeutic dose is significantly lower than the potentially toxic dose. This underscores a broad margin of safety for therapeutic applications. Moxifloxacin is generally well-tolerated at standard therapeutic doses, with adverse drug reactions becoming more prominent and severe at higher doses.<xref ref-type="bibr" rid="article-159921.r35">[35]</xref></p>
        <p>Common adverse effects at higher doses include gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain, central nervous system effects such as headache, dizziness, and confusion, musculoskeletal effects such as tendonitis or tendon rupture, particularly in older patients and those taking corticosteroids, and cardiovascular effects such as QT interval prolongation, which can lead to arrhythmias. Certain&#x000a0;severe adverse effects of moxifloxacin include tendon rupture (tendinitis and tendon rupture, commonly affecting the Achilles tendon but potentially affecting other tendons), phototoxicity (increased sensitivity to sunlight leading to sunburn-like reactions), cardiovascular effects (QTc prolongation associated with potentially life-threatening arrhythmias), and allergic reactions (skin rash, itching, and swelling), which can occur at any dose.<xref ref-type="bibr" rid="article-159921.r36">[36]</xref></p>
      </sec>
      <sec id="article-159921.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no specific antidote is available for moxifloxacin overdose. Therefore, treatment focuses primarily on symptom management and essential supportive care, including airway maintenance, oxygen supplementation, and hemodynamic support. Gastric lavage or activated charcoal may be considered to limit further drug absorption, depending on the patient's level of consciousness. If the patient is alert and capable of protecting their airway, gastric lavage or activated charcoal can be used to prevent systemic absorption.<xref ref-type="bibr" rid="article-159921.r22">[22]</xref></p>
      </sec>
      <sec id="article-159921.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Collaboration among interprofessional healthcare teams, including physicians, nurses, pharmacists, and other healthcare workers, is essential for effectively managing patients' conditions receiving moxifloxacin. Antimicrobial stewardship plays a crucial role in optimizing patient outcomes related to moxifloxacin. The interprofessional healthcare team should work collaboratively to develop a comprehensive treatment strategy when prescribing moxifloxacin, which encompasses proper dosage, duration of therapy, and potential drug interactions. A collaborative approach ensures that patient care aligns with evidence-based guidelines. All healthcare team members are ethically obligated to prioritize patients' welfare and safety, which involves regular evaluations of the necessity of moxifloxacin therapy and its associated risks and benefits.<xref ref-type="bibr" rid="article-159921.r37">[37]</xref>&#x000a0;</p>
        <p>Clinicians should communicate with other specialists involved in patient care to prevent conflicts with concurrent medications or treatments. Nurses should monitor and document patients' progress seamlessly, whereas pharmacists should be readily available to address medication-related queries.<xref ref-type="bibr" rid="article-159921.r38">[38]</xref><xref ref-type="bibr" rid="article-159921.r39">[39]</xref> For instance, when moxifloxacin is prescribed for a patient with a respiratory infection, the interprofessional healthcare team should collaborate to assess the patient's lung function, monitor for potential adverse effects such as tendonitis, and adjust the treatment plan as necessary. A randomized controlled trial demonstrated that communication gaps among healthcare providers can reduce treatment efficiency.<xref ref-type="bibr" rid="article-159921.r40">[40]</xref></p>
      </sec>
      <sec id="article-159921.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159921&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159921">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159921/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159921">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159921.s10">
        <title>References</title>
        <ref id="article-159921.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wiseman</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>363</fpage>
            <page-range>363-73; discussion 374</page-range>
            <pub-id pub-id-type="pmid">10193688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-39</page-range>
            <pub-id pub-id-type="pmid">10718103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metlay</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Musher</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Whitney</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>200</volume>
            <issue>7</issue>
            <fpage>e45</fpage>
            <page-range>e45-e67</page-range>
            <pub-id pub-id-type="pmid">31573350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mase</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bothamley</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cegielski</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fregonese</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ahmad Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kheir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lardizabal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauzardo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mangan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mitnick</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Nilsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Parvez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wortham</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chorba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seaworth</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>200</volume>
            <issue>10</issue>
            <fpage>e93</fpage>
            <page-range>e93-e142</page-range>
            <pub-id pub-id-type="pmid">31729908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talan</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Clinical perspectives on new antimicrobials: focus on fluoroquinolones.</article-title>
            <source>Clin Infect Dis</source>
            <year>2001</year>
            <month>Mar</month>
            <day>15</day>
            <volume>32 Suppl 1</volume>
            <fpage>S64</fpage>
            <page-range>S64-71</page-range>
            <pub-id pub-id-type="pmid">11249831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>[The efficacy and safety of moxifloxacin in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease].</article-title>
            <source>Zhonghua Jie He He Hu Xi Za Zhi</source>
            <year>2015</year>
            <month>May</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>366</fpage>
            <page-range>366-9</page-range>
            <pub-id pub-id-type="pmid">26463489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miravitlles</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin: a respiratory fluoroquinolone.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>1755</fpage>
            <page-range>1755-72</page-range>
            <pub-id pub-id-type="pmid">18570608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Respiratory Fluoroquinolones Monotherapy vs. &#x003b2;-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>489</fpage>
            <pub-id pub-id-type="pmid">31139081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberg</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Landersdorfer</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Rivera-Chaparro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ghazaryhan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetics of Moxifloxacin in Children.</article-title>
            <source>Paediatr Drugs</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-173</page-range>
            <pub-id pub-id-type="pmid">35284983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herath</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Nov</month>
            <day>28</day>
            <issue>11</issue>
            <fpage>CD009764</fpage>
            <pub-id pub-id-type="pmid">24288145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arshinoff</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Modabber</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>1730</fpage>
            <page-range>1730-1741</page-range>
            <pub-id pub-id-type="pmid">28007104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sippola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haijanen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;nroos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rautio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rantanen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pinta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ilves</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mattila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rintala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>L&#x000f6;yttyniemi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hurme</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tammilehto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marttila</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meril&#x000e4;inen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laukkarinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x000e4;vel&#x000e4;</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Savolainen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sippola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aarnio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paajanen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Salminen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jan</month>
            <day>26</day>
            <volume>325</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-362</page-range>
            <pub-id pub-id-type="pmid">33427870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kogan</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Ibishev</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Naboka</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Gudima</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Ismailov</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>[Extended culture study as a keypoint to rethinking antibiotic therapy for chronic bacterial prostatitis].</article-title>
            <source>Urologiia</source>
            <year>2023</year>
            <month>Mar</month>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-11</page-range>
            <pub-id pub-id-type="pmid">37401677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cicchese</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Maiello</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Borish</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Chishti</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Tomko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frye</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Fillmore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kracinovsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scanga</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Dartois</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Linderman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kirschner</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens.</article-title>
            <source>PLoS Comput Biol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>e1010823</fpage>
            <pub-id pub-id-type="pmid">37319311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive clinical evaluation of moxifloxacin: A retrospective study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Jun</month>
            <day>02</day>
            <volume>102</volume>
            <issue>22</issue>
            <fpage>e33896</fpage>
            <pub-id pub-id-type="pmid">37266643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>TAC</given-names>
              </name>
              <name>
                <surname>Lustosa</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Kogawa</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin: Physical-chemical and Microbiological Analytical Methods in the Context of Green Analytical Chemistry.</article-title>
            <source>Curr Pharm Des</source>
            <year>2023</year>
            <month>Jun</month>
            <day>06</day>
            <volume>29</volume>
            <issue>15</issue>
            <fpage>1166</fpage>
            <page-range>1166-1172</page-range>
            <pub-id pub-id-type="pmid">37190804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mundkowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drewelow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Welte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burkhardt</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>575</fpage>
            <page-range>575-8</page-range>
            <pub-id pub-id-type="pmid">18515790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guay</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin in the treatment of skin and skin structure infections.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-34</page-range>
            <pub-id pub-id-type="pmid">18360653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patek</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Frei</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).</article-title>
            <source>Drug Saf</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-22</page-range>
            <pub-id pub-id-type="pmid">31691256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Panse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber-Schoendorfer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oppermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>4392</fpage>
            <page-range>4392-8</page-range>
            <pub-id pub-id-type="pmid">24841264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r21">
          <label>21</label>
          <element-citation publication-type="book">
            <chapter-title>Moxifloxacin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baggio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ananda-Rajah</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone antibiotics and adverse events.</article-title>
            <source>Aust Prescr</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>161</fpage>
            <page-range>161-164</page-range>
            <pub-id pub-id-type="pmid">34728881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Fluoroquinolones</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31643179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majalekar</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Shirote</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolones: Blessings Or Curses.</article-title>
            <source>Curr Drug Targets</source>
            <year>2020</year>
            <volume>21</volume>
            <issue>13</issue>
            <fpage>1354</fpage>
            <page-range>1354-1370</page-range>
            <pub-id pub-id-type="pmid">32564750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baghaei</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barkane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brode</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Brust</surname>
                <given-names>JCM</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>VWL</given-names>
              </name>
              <name>
                <surname>Falzon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Isaakidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kempker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kipiani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuksa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Laniado-Labor&#x000ed;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Singla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Udwadia</surname>
                <given-names>ZF</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <collab>Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017</collab>
            </person-group>
            <article-title>Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.</article-title>
            <source>Lancet Respir Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-394</page-range>
            <pub-id pub-id-type="pmid">32192585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinkle</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Re-assessing Evidence for Adverse Ocular Reactions Associated with Fluoroquinolones: Implications for Intracameral Use.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2022</year>
            <month>Jan</month>
            <day>02</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>208</fpage>
            <page-range>208-209</page-range>
            <pub-id pub-id-type="pmid">32783748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature.</article-title>
            <source>BMC Pulm Med</source>
            <year>2022</year>
            <month>Jul</month>
            <day>19</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>279</fpage>
            <pub-id pub-id-type="pmid">35854287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oreagba</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Oshikoya</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ogar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adefurin</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Awodele</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oni</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>e00297</fpage>
            <pub-id pub-id-type="pmid">28357123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rare case report of moxifloxacin-induced persistent hiccups.</article-title>
            <source>Eur J Hosp Pharm</source>
            <year>2023</year>
            <month>Jun</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">37369596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stahlmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lode</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Safety considerations of fluoroquinolones in the elderly: an update.</article-title>
            <source>Drugs Aging</source>
            <year>2010</year>
            <month>Mar</month>
            <day>01</day>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-209</page-range>
            <pub-id pub-id-type="pmid">20210367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morales</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pacurariu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Slattery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McGettigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.</article-title>
            <source>JAMA Neurol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>76</volume>
            <issue>7</issue>
            <fpage>827</fpage>
            <page-range>827-833</page-range>
            <pub-id pub-id-type="pmid">31034074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rudra</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mallick</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Moxifloxacin-induced oral erythema multiforme: An unusual adverse effect hitherto unreported.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-300</page-range>
            <pub-id pub-id-type="pmid">34414908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briasoulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.</article-title>
            <source>Cardiology</source>
            <year>2011</year>
            <volume>120</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-10</page-range>
            <pub-id pub-id-type="pmid">22156660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Oral Fluoroquinolone and the Risk&#x000a0;of&#x000a0;Aortic Dissection.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1369</fpage>
            <page-range>1369-1378</page-range>
            <pub-id pub-id-type="pmid">30213330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ball</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Future of the quinolones.</article-title>
            <source>Semin Respir Infect</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-24</page-range>
            <pub-id pub-id-type="pmid">11562902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Smiljkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rolnitsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>El Shahed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Banihani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bitnun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Drug Monitoring of Moxifloxacin to Guide Treatment of <italic>Mycoplasma hominis</italic> Meningitis in an Extremely Preterm Infant.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2021</year>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>857</fpage>
            <page-range>857-862</page-range>
            <pub-id pub-id-type="pmid">34790077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowan</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Anjara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Br&#x000fa;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Marnane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McAuliffe</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The impact of huddles on a multidisciplinary healthcare teams' work engagement, teamwork and job satisfaction: A systematic review.</article-title>
            <source>J Eval Clin Pract</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-393</page-range>
            <pub-id pub-id-type="pmid">35174941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammond</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Development of interprofessional healthcare teamwork skills: mapping students' process of learning.</article-title>
            <source>J Interprof Care</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>589</fpage>
            <page-range>589-598</page-range>
            <pub-id pub-id-type="pmid">34346795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nygren</surname>
                <given-names>US</given-names>
              </name>
              <name>
                <surname>Tindberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nordgren</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Healthcare professionals' perceptions about interprofessional teamwork: a national survey within Swedish child healthcare services.</article-title>
            <source>BMC Health Serv Res</source>
            <year>2021</year>
            <month>Mar</month>
            <day>22</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>265</fpage>
            <pub-id pub-id-type="pmid">33752664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159921.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schwind</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fortune</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Sutyak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Van Eaton</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Azzie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Boehler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dunnington</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Surgeon information transfer and communication: factors affecting quality and efficiency of inpatient care.</article-title>
            <source>Ann Surg</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>245</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-69</page-range>
            <pub-id pub-id-type="pmid">17245166</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
